基于米诺环素/阿莫西西林的比斯木斯四重疗法用于杆菌根除:试点研究
Senlin You1,2, Xiaoqiong Tang1,2, Jiarui Zhou1,2
1West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.
Microorganisms
|March 28, 2024
概括
基于米诺环素/阿莫西西林的芝麻四倍疗法 (BQT) 提供了一种安全有效的替代方案,用于根除Helicobacter pylori. 这种方法显示了高的根除率,特别是在以前治疗过H. pylori感染的患者中.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 微生物学 微生物学
背景情况:
- 针对H.pylori根除的古典木四倍疗法 (BQT) 面临着挑战,原因是四环素和甲尼达的副作用和复杂的管理.
- 开发替代BQT方案对于改善患者遵守和治疗结果至关重要.
研究的目的:
- 评估基于米诺环素/阿莫西西林的BQT对H. pylori根除的疗效和安全性.
- 为了评估H. pylori分离物对米诺环素的敏感性,与四环素相比.
主要方法:
- 使用E-试验条对101个H. pylori分离物对四环素和米诺环素的敏感性测试.
- 一项试点研究涉及114名患者 (以前未接受过治疗和经验丰富的患者),接受了为期14天的基于米诺环素/氨基素的BQT疗法.
- 该疗法包括埃索梅普拉或诺普拉赞,慕合性pectin,阿莫西西林和minocycline,每天服用两次.
主要成果:
- 在H. pylori分离物中,米诺环素耐药性为零,而四环素耐药性为3.0%.
- 整体治疗意图 (ITT) 和每协议 (PP) 根除率分别为94.7%和97.3%.
- 在未经治疗的 (ITT 91.7%,PP 95.7%) 和经过治疗的 (ITT 100%,PP 100%) 患者中观察到高根除率. 没有报告任何严重的不良事件.
结论:
- 基于米诺环素/阿莫西西林的BQT证明了H. pylori根除的卓越有效性和安全性.
- 在测试的分离物中缺乏米诺环素耐药性,支持其作为H. pylori治疗方案中可靠成分的潜力.
- 这种疗法为经典BQT提供了一个有希望的替代方案,有可能提高临床适用性.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
390
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
390
01:26Peptic Ulcer Disease IV: Management
91
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
91
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
443
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
443
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
404
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
404
01:23Gastritis III: Clinical Manifestations and Management
235
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
235
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
116
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
116